Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience

被引：2

作者：

Isik, Metin ^{[1
]}

Halacli, Burcin ^{[2
]}

Atmaca, Ozgur ^{[2
]}

Etgul, Sezgin ^{[2
]}

Dogan, Ismail ^{[1
]}

Kilinc, Levent ^{[1
]}

Calguneri, Meral ^{[1
]}

机构：

[1] Hacettepe Univ Hosp, Dept Internal Med, Div Rheumatol, TR-06100 Ankara, Turkey

[2] Hacettepe Univ, Dept Internal Med, Ankara, Turkey

来源：

RHEUMATOLOGY INTERNATIONAL | 2013年 / 33卷 / 06期

关键词：

Triple DMARD therapy; Rheumatoid arthritis; Resistant disease; THERAPY; TRIAL; COST;

D O I：

10.1007/s00296-012-2546-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The mainstay of RA treatment is the disease-modifying antirheumatic drugs, and triple DMARD combination is now known to be better than monotherapies. Our aim in this trial was to report our clinical experience with triple DMARD therapy for resistant rheumatoid arthritis. Data of 140 patients with RA resistant to methotrexate and steroid combination were evaluated retrospectively. One hundred and nineteen (85 %) were female, and the median age at diagnosis was 56 (29-82) years. The median time between the diagnosis and beginning of triple therapy was 45.5 (6-564) months. Fifty-two (37.1 %) patients (group 1) on triple therapy protocol achieved remission, but the others (88; 62.9 %) (group 2) did not. The mean DAS28 scores for the study group before triple DMARD therapy and after 12 months under triple DMARD therapy were 4.93 and 3.24, respectively. The DAS28 scores after 12 months for groups 1 and 2 were 2.57 and 3.64. The median follow-up period for patients in group 1 was 60 months (23-118), and the mean DAS28 score at the time of the analysis for group 1 was 2.36. Triple DMARD combination may save one-third of the MTX-resistant RA patients from the serious side effects and the cost of anti-TNF.

引用

页码：1425 / 1427

页数：3

共 10 条

[1]

Callahan LF, 1999, RHEUMATOID ARTHRITIS, V2, P3

[2]

Choi HK, 2002, J RHEUMATOL, V29, P1156

[3]

Choi KH, 2000, ARTHR RHEUM, V43, P2316

[4] Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care [J].

Curtis, Jeffrey R. ;

Singh, Jasvinder A. .

CLINICAL THERAPEUTICS, 2011, 33 (06) :679-707

[5] Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs [J].

Dale, James ;

Alcorn, Nicola ;

Capell, Hilary ;

Madhok, Rajan .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (08) :450-458

[6] Methotrexate and emerging therapies [J].

Kremer, JM .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (03) :651-+

[7]

Lie E, 2011, ANN RHEUM DIS

[8] Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate -: A two-year randomized trial [J].

Svensson, B ;

Boonen, A ;

Albertsson, K ;

van der Heijde, D ;

Keller, C ;

Hafström, I .

ARTHRITIS AND RHEUMATISM, 2005, 52 (11) :3360-3370

[9] Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects - A randomized, double-blind, placebo-controlled clinical trial [J].

van Everdingen, AA ;

Jacobs, JWG ;

van Reesema, DRS ;

Bijlsma, JWJ .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (01) :1-12

[10] THE ECONOMIC COST AND SOCIAL AND PSYCHOLOGICAL IMPACT OF MUSCULOSKELETAL CONDITIONS [J].

YELIN, E ;

CALLAHAN, LF ;

ARNETT, F ;

DENNIS, D ;

DEYO, R ;

FELSON, D ;

FELTS, W ;

GIANNINI, E ;

HELMICK, C ;

HEYSE, S ;

HIRSCH, R ;

HOCHBERG, M ;

HUNDER, G ;

LAWRENCE, R ;

LIANG, M ;

PILLEMER, S ;

SHULMAN, L ;

STEEN, V ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1995, 38 (10) :1351-1362

← 1 →